Effects of bile-acid-binding resin (colestimide) on blood glucose and visceral fat in Japanese patients with type 2 diabetes mellitus and hypercholesterolemia: an open-label, randomized, case-control, crossover study

详细信息	查看全文 | 推荐本文 |

• 作者：Tatsuya Suzuki^a ; ^{t-suzuki@nms.ac.jp} ; Kenzo Oba^a ; Yoshimasa Igari^a ; Kentaro Watanabe^a ; Noriaki Matsumura^a ; Shoko Futami-Suda^a ; Motoshi Ouchi^a ; Kazunari Suzuki^a ; Ken-ichi Sekimizu^a ; Yoshiaki Kigawa^b ; Hiroshi Nakano^a
• 关键词：Colestimide ; Blood glucose ; Visceral fat ; Type 2 diabetes mellitus
• 刊名：Journal of Diabetes and its Complications
• 出版年：2012
• 期刊代码：154_10568727
• 类别：med
• 出版时间：January-February, 2012
• 卷：26
• 期：1
• 页码：34-39
• 文件大小：547 K

摘要

Objective

The objective was to examine the effects of colestimide on blood glucose, visceral fat, adipocytokines, and bile acid conjugate fractions in Japanese patients.

Methods

This study was an open-label, randomized, case-control, crossover study of colestimide 3 g/day in 40 Japanese patients with type 2 diabetes mellitus (T2D) and hypercholesterolemia. Patients were assigned to the colestimide group in which pravastatin and colestimide were administered orally and to the statin group in which pravastatin alone was administered orally. The principal outcome measures were serum lipid levels, fasting plasma glucose level in the early morning, hemoglobin A1c (HbA_1c), visceral fat area (VFA), and serum 1,5-anhydroglucitol (1,5-AG) level.

Results

Serum low-density lipoprotein cholesterol levels significantly decreased from 113卤38 mg/dl at baseline to 90卤20 mg/dl (P=.009) at week 12 of colestimide administration. HbA_1c significantly decreased from 7.4%卤0.9%at baseline to 6.9%卤0.9%(P=.001) at week 12 of colestimide administration. Serum 1,5-AG levels increased from 9.4卤10.1 渭g/ml to 12.4卤9.5 渭g/ml (P=.05) at week 12 of colestimide administration. The statin group showed no significant changes in lipids and 1,5-AG. However, 螖VFA was inversely correlated with 螖cholic acid, and multivariate analysis revealed that 螖VFA was a significant explanatory variable.

Conclusions

Colestimide holds promise not only for the treatment of hypercholesterolemia but also for the possible improvement of T2D and visceral fat obesity.